Galapagos (GLPG) said Thursday that GLPG3667 reached the primary endpoint in a dermatomyositis trial.

GLPG3667 showed a "statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity" compared with placebo, the company said.

Meanwhile, in a systemic lupus erythematosus trial, GLPG3667 demonstrated "numerical improvements on several secondary endpoints" compared with placebo, but it did not reach "statistical significance in primary endpoint analysis," Galapagos said.

Galapagos said Gilead (GILD) has agreed to temporarily waive some rights under a 10-year option, licensing and collaboration deal between the companies, allowing Galapagos to seek external partnership opportunities for GLPG3667.